Understanding Minimal Residual Disease (MRD)
Understanding Minimal Residual Disease (MRD): A Helpful Calculation when Analyzing ctDNA Minimal residual disease (MRD) detection through circulating...
About Us
- Home
- About Us
About
Who we are
LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.
Some key statistics of our assay
- Sensitivity for Genotyping (SNPs / InDels) > 93%
- Specificity for Genotyping (SNPs / InDels) > 99.999%
- Sensitivity for MRD detection at MRD level of > 10-5 > 88%
- Specificity for MRD detection at MRD level of > 10-5 > 99%
- Limit of Detection for MRD ~5 x 10-6
Awards
Certifications & Standards
We work in conformity with the RiliBÄK guidelines of the German Medical Association
Certification Process Ongoing
In clinical trials we work in conformity with ICH-GCP (Good Clinical Practice)
Our Team
You will be able to find our team here soon!
How We Work
Partner with us
We are always on the lookout for collaborators.
Academic research, start-up or pharmaceutical industry. If you are excited about blood-based cancer genomics or highly sensitive minimal residual disease assessment across cancers we should start a conversation.
Get in contact with us and let us explore how we can team up.
Our Team
Meet With Our Doctor
Our Blog
Lates News & Articles
Lookout for collaborators
We are always on the lookout for collaborators. Academic research, start-up or pharmaceutical industry. If you are excited...